Thousand Oaks Bio Completes $235 Million Round for CDMO Ops

Thousand Oaks Biopharma, headquartered in Nantong , completed a $235 million Series D financing to support its biologic CDMO operations. In 2017, TOBio was founded when it decided to integrate its core cell culture medium business, which was founded in 2011 as JSBio, with CDMO services, offering a one-stop solution from raw materials to complete CMC services. The company has global operations with production bases and R&D laboratories in Nantong , Shanghai , Lanzhou , Gansu and Los Angeles . The D round was completed last month. More details.... Share this with colleagues: // //